



EASD (European Association for the Study of Diabetes) 2025

September 15-19, 2025; Vienna, Austria (+Virtual); Resource Hub

---

**Welcome to our resource hub for EASD 2025!** This is a one-stop-shop for all your EASD 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

**Important Conference Information.** For those who cannot travel to Vienna, the conference will continue to be held in a traditional format, with the excellent “plus” that everything is recorded and goes on the EASD website each evening. We have great appreciation for EASD’s virtual platform given the superb performance of the platform over multiple decades and given EASD’s longtime practice of recording sessions. See the conference [website](#) and the [agenda](#), register [here](#), and read our preview [here](#).

## Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Diabetes Therapy Highlights](#)

[Diabetes Technology Highlights](#)

[Diabetes Big Picture Highlights](#)

[Previous EASD Coverage on CCKB](#)

## Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Day-by-Day Conference Preview](#)
4. [Conference Program](#)

## Day-of Conference Reports

1. [EASD 2025 Day #1 Highlights](#)
2. [EASD 2025 Day #2 Highlights](#)
3. [EASD 2025 Day #3 Highlights](#)
4. [EASD 2025 Day #4 Highlights](#)
5. [EASD 2025 Day #5 Highlights](#)

## Diabetes Therapy Highlights

1. [Prof. Heerspink, Roden, and Bozkurt](#) highlight the potential for SGLT-2 inhibitor and GLP-1 RA combination therapy for cardiorenal protection
2. [Revolutionizing cardiometabolic health](#): Novo Nordisk’s industry symposium focuses on the kidney, liver, and weight management
3. [Lilly symposium highlights the evolving and crucial role](#) of CVOTs in T2D management
4. [Amgen’s symposium highlights the roles of GIP receptor agonism/antagonism](#) and once-monthly MariTide in metabolic diseases; Dr. Donna Ryan: a “golden age” of obesity development

5. [Post-hoc analysis of SOUL trial finds CV benefits](#) of Rybelsus (oral semaglutide) regardless of baseline A1c or BMI
6. [Full phase 2 results of dual GLP-1/GIP RA HRS9531](#) for overweight or obesity without T2D
7. [The role of incretin-based](#) treatments in T1D management
8. [ELSA study shows acceptability and feasibility](#) of general population screening for pre-symptomatic T1D among children in the UK
9. [Post-hoc analysis of phase 3 REDEFINE-1 trial](#): Long-acting amylin analog cagrilintide confers greater weight loss (12%) than placebo (2.3%)
10. [Discussion with Dr. Alice Cheng, Prof. Francesco Giorgino, and Prof. Ezio Bonifacio](#) on population-wide, age-indiscriminate screening for T1D
11. [Insulin therapy and cardiorenal outcomes in T2D](#): A pooled analysis of CANVAS and CREDENCE
12. [Phase 3 study finds A1c reduction](#) and potential cardiorenal protection with berberine ursodeoxycholate
13. [Full results of phase 3 ATTAIN-1 trial](#): Lilly's once-daily GLP-1 orforglipton demonstrates 11% weight loss in people with obesity
14. [Phase 3 REDEFINE 2 trial](#): CagriSema significantly increases Time in Range in people with obesity and T2D, per secondary analysis
15. [TIRTLE1 T1D trial shows that Lilly's once-weekly GLP-1/GIP tirzepatide](#) reduces weight (9%) and insulin dose (33%) and improves body composition
16. [Oral quadruple agonist NA-831 for obesity](#): Topline phase 2 results suggest weight loss without muscle loss and GI-related side effects
17. [Incretin-associated sarcopenia](#): Does it matter which treatment?
18. [Phase 2b COURAGE trial](#): Regeneron's trevogrumab help preserve 50-80% of lean mass lost with semaglutide alone
19. [Amycretin demonstrates favorable pharmacokinetics](#), safety, and tolerability in people with renal impairment
20. [Precision medicine in T2D](#): Targeting GLP-1 RAs and SGLT-2 inhibitor combination treatment for kidney protection
21. [Phase 2b PROGRESS trial results show AAK1 inhibitor pilavapadin \(LX9211\)](#) reduces pain in DPN; findings support phase 3 trial for 10 mg dose
22. [Additional CATALYST trial insights and perspectives](#) on the current hypercortisolism diagnostic cutoff from UNC's Dr. John Buse
23. [Pooled analysis of SOUL, FLOW, and STRIDE](#): Semaglutide reduces major adverse limb events by 30% compared to placebo
24. [Trends of SGLT-2 inhibitor use in T2D in the UK](#): Up to 90% with T2D and CKD eligible, but uptake not yet optimal
25. [Real-world study finds semaglutide is associated with 23% reduced MACE](#) compared to dulaglutide in people with T2D and CVD
26. [Zealand's once-weekly dual GLP-1/GLP-2 RA dapigliptide](#) confers up to 8% weight loss at Week 13
27. [Full results of SURPASS-CVOT](#): Tirzepatide reduces MACE numerically by 8%
28. [Additional results of SURPASS-CVOT](#): Tirzepatide significantly reduces weight and glycemic outcomes
29. [SURPASS-PEDS](#): Tirzepatide dropped A1c by 2.3 percentage points from undisclosed baseline; first GLP-1 RA to demonstrate clinically meaningful weight loss (-9.1%) in youth with T2D
30. [STEP UP prespecified post-hoc studies](#) reveal positive effects on body composition, proximal muscle strength, and control of eating with semaglutide 7.2 mg

31. [EASD-EASL joint symposium](#): Bridging the gap with improved screening and the use of combination therapies
32. [Prespecified analysis of phase 2 CONFIDENCE trial](#): simultaneous use of finerenone (Bayer's Karendia) and empagliflozin (BI/Lilly's Jardiance) prompted far better outcomes while addition of GLP-1 yielded nothing additional
33. [New paths for old friends](#): Potential new roles for GLP-1 RAs and SGLT-2 inhibitors
34. [INNODIA's phase 2 MELD-ATG trial finds low-dose ATG](#) significantly preserves C-peptide levels in young individuals with new-onset T1D
35. [In Ver-A-T1D trial, verapamil](#) confers non-statistically significant preservation in C-peptide in new-onset T1D
36. ["There's no insulin like your own"](#): Two-year outcomes of the BANDIT trial demonstrate JAK inhibitor baricitinib preserves C-peptide
37. [Do we need really need a large outcome trial](#) to prove the cardiorenal benefits of SGLT-2 inhibitor and GLP-1 RA combination use?
38. [Benefits and challenges of AI-assisted screening for diabetic retinopathy](#) and an overview of the eye health treatment landscape
39. **\*NEW\*** [GIP infusion alone or in addition to semaglutide shows no improvement in glucose](#) levels or body weight in T2D
40. [Pooled analysis demonstrates the safety and efficacy of semaglutide](#) among people with CKD also on dialysis
41. [GLP-1 RA-based therapies and impact fertility](#), pregnancy, and early-onset T2D in women

## Diabetes Technology Highlights

1. [CGM and DGK](#): Dr. Bergenstal highlights technology-enabled improvements in T1D and T2D management
2. [Expanding the horizons of MiniMed 780G](#): Evidence supports use in children, pregnancy, and for T2D
3. [Dexcom COO Mr. Jake Leach spotlights CGM](#) as a tool for reducing diabetes complications and enhancing therapy optimization
4. [Roche's Accu-Chek SmartGuide CGM: Real-world data \(n=249\)](#) shows significant reduction (20%) in nocturnal hypoglycemic events with Night Low Predict feature
5. [Three years of MiniMed 780G](#): Durable glycemic outcomes, reduced burden, and strengthened patient confidence
6. [Glycemic improvements with Tandem's Control-IQ](#) at 12 months maintained at 24 months
7. [Safety and accuracy of CGM for inpatient DKA](#) management compared to hourly POC testing
8. [International RCT finds CGM reduces risk](#) of large-for-gestational-age infants in women with GDM
9. [Automation in complexity](#): MiniMed 780G shows strength in T2D and other populations
10. [A look to the FDA's iCGM requirements](#): Evolving the minimum expectations for CGM market authorization in the EU
11. [Defining provider roles in diabetes technology](#): The University of Leicester's four-level competency framework
12. [EASD Expert Session with Prof. Sabine Hofer and Dr. Amit Gupta](#): Education, reimbursement, and safety remain central to diabetes technology adoption across global settings
13. [Risk factors for severe hypoglycemia in older adults](#): Insights from the iNPHORM study
14. [Control-IQ in focus](#): A review of clinical strategies and 2025 OUS software updates
15. [Medtronic shares clinical pearls for using smart MDI](#): Improving outcomes and simplifying decision making
16. [Evidence supports benefit of CGM](#) for reduction of severe, recurrent hypoglycemia
17. [Trust as the cornerstone](#): CGM, AID, and AI in the next era of diabetes care
18. [Diabetes technology for pregnancy](#): Bridging gaps between evidence and guidelines

19. [Exercise and AID](#): Insights from the RAPPID study on hypoglycemia risk
20. [GRACE and DipGluMo](#) show the huge power of CGM's role in GDM management
21. [MiniMed 780G vs. Control-IQ](#): Handling unannounced meal in adolescents with T1D
22. [New insights in glycemc management](#): Sleep duration, pregnancy, and a head-to-head comparison of three CGMs during exercise
23. **\*NEW\*** [Insulet-sponsored symposium](#) emphasizes scalable onboarding strategies and real-world outcomes with Omnipod 5 in T1D
24. **\*NEW\*** [CGM use in hospitals](#): Clinical benefits and implementation challenges
25. **\*NEW\*** [CGM as a routine for T2D](#): Evidence from RCTs, real-world data, and case studies
26. **\*NEW\*** [Nationwide French data](#) highlight durability and glycemc gains associated with AID use
27. **\*NEW\*** [CamAPS FX and Control-IQ improve glycemc](#) and neonatal outcomes vs. MiniMed 780G in pregnant women with T1D; strong outcomes across all systems

## Diabetes Big Picture Highlights

1. [CKD and T1D](#): Profs. Heerspink and Rossing argue status quo must change
2. [Vienna welcomes nearly 13,500 participants](#) with diabetes posters spotted in airport, buildings, and subways
3. [Prof. Chantal Mathieu delivers most-valuable EASD Presidential Address](#), extolling vision for personalized, global diabetes care
4. [Under promise and over deliver](#): Dr. Dan Drucker on his philosophy for scientific research
5. [57th Claude Bernard Lecture by the esteemed Professor Andrew Hattersley focuses on "precision diabetes"](#): *Learning from the rare and applying to the common*
6. [Novel diabetes subgroup classifications](#) and optimized treatment plans based on glucose variability patterns from CGM data
7. [Fructose consumption](#) may play a key role in the development of MASLD
8. [Exhibit Hall opens with high energy](#), featuring aromatic coffee stations, free lipid tests, and photoboosts
9. [An early look into the Breakthrough T1D-led early-stage T1D screening consensus document](#): Recommendations on who, what, when, where, how
10. [Prof. Mikael Rydén receives the Camillo Golgi Prize](#) for expanding knowledge of white adipose tissue and its role in diabetes
11. [19th Albert Renold Lecture](#): Prof. Raphael Scharfmann on pancreatic development as a key to discover unexpected treatments of diabetes
12. [EASD draft guidelines aim to bring diabetes distress](#) assessment and management into routine care
13. [Global analysis finds that diabetes](#) is the largest contributor to sugar-sweetened beverage-related deaths
14. [Building the future of diabetes care](#): Prof. Tadej Battelino receives diaTribe Solvable Problems' Vanguard Leadership Award
15. [Systematic analysis of the Global Burden of Disease](#) reports major large-scale findings on prediabetes prevalence from 1990 to 2023
16. [60th Minkowski Lecture](#): Dr. Teresa Mezza on prioritizing the pancreas in T2D
17. [Dr. Steven Kahn and Prof. Roy Taylor](#) on new-age incretin therapies as a path to T2D remission
18. [Hyperglycemic crises](#): Q&A offers insight into best practice guidelines on DKA management
19. [EASD-CEDA Joint Symposium](#): Diabetic complications in the era of precision medicine
20. [EASD Diabetes Global Impact](#) Prize Lecture

21. [Rethinking A1c](#): Genetics, aging, and CGM differences challenge the “one-size-fits-all”
22. [C-peptide measurements](#) to improve classifications of diabetes in routine clinical practice
23. [Significant increases in dementia-related mortality](#) in people with diabetes compared to those without
24. [New insights into persistent](#) and increasing burdens of diabetes morbidity
25. [Higher A1c thresholds required to predict T1D progression](#) in adults compared to children with positive islet autoantibody
26. [“The era of diagnosis”](#): Survival rates for T1D increased over decades

### **Previous EASD Coverage on CCKB**

1. [EASD 2024 Full Report](#)
2. [EASD 2023 Full Report](#)
3. [EASD 2022 Full Report](#)
4. [EASD 2021 Full Report](#)
5. [EASD 2020 Full Report](#)
6. [EASD 2019 Full Report](#)
7. [EASD 2018 Full Report](#)
8. [EASD 2017 Full Report](#)
9. [EASD 2016 Full Report](#)
10. [EASD 2015 Full Report](#)